Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genentech Eyes Top Oncology Spot By 2010; No Near-Term Avastin Competitor

Mar 29 2004

• By The Pink Sheet

Related Content

Oncology R&amp;D: Exploiting New Molecular Targets Is Challenge for 2003

Dec 30 2002

Genentech R&D Spending Will Be 18% Of Revenue; Small Molecules In Plan

Mar 29 2004

Genentech Avastin Clears FDA; Colorectal Cancer Drug Costs $4,400 A Month

Mar 01 2004

Genentech Self-Portrait For 2005

Feb 08 1999

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window